220 related articles for article (PubMed ID: 15344542)
1. [Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients].
Fujiwara Y; Higuchi K; Yamamori K; Watanabe Y; Shiba M; Watanabe T; Tominaga K; Oshitani N; Matsumoto T; Arakawa T
Nihon Rinsho; 2004 Aug; 62(8):1510-5. PubMed ID: 15344542
[TBL] [Abstract][Full Text] [Related]
2. [Test of refractory gastroesophageal reflux disease].
Shimoyama Y; Kuribayashi S; Maeda M; Kusano M
Nihon Rinsho; 2004 Aug; 62(8):1475-82. PubMed ID: 15344537
[TBL] [Abstract][Full Text] [Related]
3. [Management of gastroesophageal reflux disease (GERD) with refractory to standard dose of proton pump inhibitor].
Iwakiri K; Kawami N; Tanaka Y; Sano H; Kotoyori M; Sakamoto C
Nihon Rinsho; 2007 May; 65(5):913-20. PubMed ID: 17511233
[TBL] [Abstract][Full Text] [Related]
4. [PPI: new strategies for GERD].
Hoshino E; Ishiyama A; Tsuchida T
Nihon Rinsho; 2004 Aug; 62(8):1570-6. PubMed ID: 15344553
[TBL] [Abstract][Full Text] [Related]
5. [GERD guideline].
Hongo M
Nihon Rinsho; 2004 Aug; 62(8):1421-6. PubMed ID: 15344529
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms.
Egan LJ; Myhre GM; Mays DC; Dierkhising RA; Kammer PP; Murray JA
Aliment Pharmacol Ther; 2003 Jun; 17(12):1521-8. PubMed ID: 12823155
[TBL] [Abstract][Full Text] [Related]
8. Modern achievements in the diagnosis and treatment of the refractory gastroesophageal reflux disease.
Ivashkin VT; Maev IV; Trukhmanov AS; Rumyantseva DE
Ter Arkh; 2018 Aug; 90(8):4-12. PubMed ID: 30701934
[TBL] [Abstract][Full Text] [Related]
9. Drugs, bugs, and esophageal pH profiles.
Robinson M
Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
[TBL] [Abstract][Full Text] [Related]
10. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Furuta T; Shirai N; Watanabe F; Honda S; Takeuchi K; Iida T; Sato Y; Kajimura M; Futami H; Takayanagi S; Yamada M; Ohashi K; Ishizaki T; Hanai H
Clin Pharmacol Ther; 2002 Oct; 72(4):453-60. PubMed ID: 12386647
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.
Kawami N; Takenouchi N; Umezawa M; Hoshino S; Hanada Y; Hoshikawa Y; Sano H; Hoshihara Y; Nomura T; Uchida E; Iwakiri K
Digestion; 2017; 95(2):140-145. PubMed ID: 28161707
[TBL] [Abstract][Full Text] [Related]
12. [Recent view of gastro-esophageal reflux disease according to the guideline for gastric ulcer treatment].
Shirakawa K; Nakamura T; Masuyama H; Hiraishi H; Terano A
Nihon Rinsho; 2004 Aug; 62(8):1559-64. PubMed ID: 15344551
[TBL] [Abstract][Full Text] [Related]
13. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Furuta T; Sugimoto M; Shirai N; Ishizaki T
Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
15. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
16. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.
Hillman L; Yadlapati R; Thuluvath AJ; Berendsen MA; Pandolfino JE
Dis Esophagus; 2017 Sep; 30(9):1-15. PubMed ID: 28859358
[TBL] [Abstract][Full Text] [Related]
17. Critical issues in the management of gastroesophageal reflux disease.
Freston JW; Malagelada JR; Petersen H; McCloy RF
Eur J Gastroenterol Hepatol; 1995 Jun; 7(6):577-86. PubMed ID: 7552644
[TBL] [Abstract][Full Text] [Related]
18. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
19. [Acid-suppressive strategy against gastroesophageal reflux diseases and non-erosive reflux diseases: the alternative of proton- pump inhibitors or H2 receptor antagonists].
Ishino Y; Sugano K
Nihon Rinsho; 2007 May; 65(5):891-4. PubMed ID: 17511229
[TBL] [Abstract][Full Text] [Related]
20. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient.
Furuta T; Takashima M; Shirai N; Xiao F; Hanai H; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2000 Jun; 67(6):684-9. PubMed ID: 10872651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
